Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
The Atlanta Braves can be optimistic about another trip to the playoffs, even after a relatively quiet offseason. While the front office added Jurickson Profar, it has not addressed the losses of ...
Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...
At close: 13 March at 12:21:27 pm GMT-4 ...
As of March 6 at 11:44:23 a.m. EST. Market Open.
As of March 6 at 11:44:23 a.m. EST. Market Open.
After hours: March 6 at 4:06:59 PM EST ...
As of 8:59:03 pm GMT-4. Market open.
As of 13 March at 3:36:48 pm GMT-4. Market open.
At close: 7 March at 3:22:49 pm GMT-5 ...
At close: March 7 at 1:52:04 PM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback